How to Use Primary Cells to Develop the Next Therapy
Human primary cells are cells isolated directly from tissues, including blood and bone marrow. The use of human primary cells increases the physiological relevance of cell culture systems, enabling you to generate meaningful data that is more predictive of in vivo outcomes. Learn about the advantages of starting with human primary cells for your immunology and cell therapy research workflows. Key considerations for choosing the ideal starting material, donor characterization, regulatory challenges, and tips to streamline your cell-based assays with human primary and cultured cells are also covered.
“Printing Human Tissues” Featuring Dr. Anthony Atala
On this episode of the Stem Cell Podcast, Dr. Anthony Atala from the Wake Forest Institute for Regenerative Medicine discusses tissue engineering, vascularization, and prioritizing safety when studying lab-grown organs.
Non-Viral CRISPR Knock-In Anti-B7-H3 CAR-T Cells Are Amenable for Treatment of Subtypes of Small Cell Lung Cancer
In this webinar, Scientist Vimal Keerthi discusses his work on identifying CD276 (B7-H3) overexpression in primary human SCLC and developing a non-viral CRISPR-Cas9 knock-in (CKI) based platform against B7-H3 to manufacture CAR T cells for the treatment of SCLC. He demonstrates the feasibility of this CAR T manufacturing platform and how this provides a blueprint for immediate clinical translation, overcoming the bottleneck of viral vector production.
Daniel Gray, PhD
Dr. Daniel Gray describes his work studying cell death and the potential applications in drug development for immune disorders
Scaling Biomimetic Culture of Pluripotent Stem Cells
Hear from Dr. Maxime Feyeux, who discusses what the in vivo growth environment of pluripotent stem cells (PSCs) can teach us about in vitro culture. He summarizes some of the current challenges facing standard PSC culture technologies and shares a solution for mass producing high-quality PSCs for downstream applications.
Nature Research Round Table: Retinal Cell Therapy Using Human Embryonic Stem Cells
Dr. Peter Coffey from University College London shares his work with the London Project to Cure Blindness, which resulted in the first clinical stem cell trial to treat blindness, and discusses cell quality requirements for clinical trials. This presentation and the following Q&A session were moderated by Dr. Christine Mummery from the Leiden University Medical Center.
This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.
Note: Some original data from this presentation has been omitted to abide by copyright rules.
Next-Generation Cell Isolation Solutions for T Cell Therapy Research
Join this talk, presented by Dr. Amanda Durkin and Q&A guest Dr. Frann Antignano, to learn about STEMCELL’s cell isolation solutions for fast and easy T cell isolation. This presentation will also focus on large-scale research strategies by introducing our new mobilized leukopaks and feature the Easy 250 EasySep™ Magnet—a scalable and efficient system for manual column-free isolation.